Open Label Dose Escalation Trial of an Adaptive Natural Killer (NK) Cell Infusion (FATE-NK100) With Subcutaneous IL-2 in Adults With Refractory or Relapsed Acute Myelogenous Leukemia (AML)

Trial Profile

Open Label Dose Escalation Trial of an Adaptive Natural Killer (NK) Cell Infusion (FATE-NK100) With Subcutaneous IL-2 in Adults With Refractory or Relapsed Acute Myelogenous Leukemia (AML)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Jun 2018

At a glance

  • Drugs FATE NK100 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; First in man
  • Acronyms VOYAGE
  • Most Recent Events

    • 29 Dec 2017 Planned number of patients changed from 29 to 20.
    • 10 Nov 2017 Results presented in a Fate Therapeutics Media Release.
    • 10 Nov 2017 According to a Fate Therapeutics media release, data were presented at the Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top